The NLRP3 inhibitor MCC950 can significantly block NLRP3 expression and ameliorate NASH pathology and lipid deposition in MCD-fed and foz/foz-induced NASH mouse models and hepatic NLRP3, procaspase-1, active caspase-1, pro-IL-1β, and IL-1β levels were significantly decreased (Mridha et al., 2017). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.